Experience
Ariad Pharmaceutical
Eli Lilly and Company
The U.S. Court of Appeals for the Federal Circuit, in an en banc opinion, confirmed the existence of a separate written description requirement that ensures that inventors have actually invented and described the subject matter claimed in their patents. The decision reversed a jury verdict against Finnegan client Eli Lilly and Company. Lilly had previously been found liable for infringing Ariad’s ’516 patent, and the jury had awarded Ariad a multi-million dollar verdict. The en banc opinion held that the asserted claims of the ’516 patent failed to satisfy the written description requirement of section 112 and were thus invalid.
Ariad Pharmaceutical v. Eli Lilly and Company, 1:02-cv-11280, D. Mass., Judge Zobel
Eli Lilly and Company v. Ariad Pharmaceutical, 08-1248, Fed. Cir., Judges Bryson, Dyk, Gajarsa, Linn, Lourie, Mayer, Michel, Moore, Newman, Prost, Rader
Federal Circuit win for Eli Lilly’s Xigris®, a recombinant form of human Activated Protein
Eli Lilly and Company
DuPont prevails on a written description defense to patent infringement at the Federal Circuit
DuPont Nutrition Biosciences APS
Eli Lilly and Company
Cumberland Pharmaceuticals
Federal Circuit vacates IPR rulings in two appeals in favor of Finnegan client PPC Broadband
PPC Broadband
Telcordia Technologies
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.